Utility of Serum Ferritin for Predicting Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Patients with Long COVID
Journal of Clinical Medicine · 18.07.2023 · 12 (14) · 4737
DOI: 10.3390/jcm12144737 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 18.07.2023. Verfasst von Yukichika Yamamoto und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, JSPS KAKENHI, Okayama Medical Foundation.
Abstract (Originalsprache)
Objective
The most common symptom of post-acute coronavirus disease 2019 (COVID-19) is fatigue, and it potentially leads to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS); however, a specific prognosticator is lacking. We aimed to elucidate the clinical characteristics of patients who developed ME/CFS after COVID-19.
Methods
In this retrospective observational study, patients who visited Okayama University Hospital for long COVID between February 2021 and March 2022 were investigated.
Results
Of the 234 patients, 139 (59.4%) had fatigue symptoms. Fifty patients with fatigue symptoms (21.4%) met the criteria for ME/CFS (ME/CFS group), while the other 89 patients did not (non-ME/CFS group); 95 patients had no fatigue complaints (no-fatigue group). Although the patients’ backgrounds were not significantly different between the three groups, the ME/CFS group presented the highest scores on the self-rating symptom scales, including the Fatigue Assessment Scale (FAS), EuroQol, and the Self-Rating Depression Scale (SDS). Furthermore, serum ferritin levels, which were correlated with FAS and SDS scores, were significantly higher in the ME/CFS group (193.0 ng/mL, interquartile range (IQR): 58.8–353.8) than in the non-ME/CFS group (98.2 ng/mL, 40.4–251.5) and no-fatigue group (86.7 ng/mL, 37.5–209.0), and a high serum ferritin level was prominent in female patients. Endocrine workup further showed that the ME/CFS group had higher thyrotropin levels but lower growth hormone levels in serum and that insulin-like growth factor-I levels were inversely correlated with ferritin levels (R = −0.328, p < 0.05).
Conclusions
Serum ferritin level is a possible predictor of the development of ME/CFS related to long COVID, especially in female patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.
ORCID-Profile: Yukichika Yamamoto, Yuki Otsuka, Kazuki Tokumasu, Yasuhiro Nakano, Hiroyuki Honda, Hideharu Hagiya, Fumio Otsuka
Förderung
- Japan Society for the Promotion of Science
- JSPS KAKENHI
- Okayama Medical Foundation
- Japanese Society of Hospital General Medicine
- Ryobi Teien Memory Foundation (2022)
Zitieren
APA
Yamamoto, Y., Otsuka, Y., Tokumasu, K., Sunada, N., Nakano, Y., Honda, H., Sakurada, Y., Hasegawa, T., Hagiya, H., & Otsuka, F. (2023). Utility of Serum Ferritin for Predicting Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Patients with Long COVID. Journal of Clinical Medicine, 12(14), 4737. https://doi.org/10.3390/jcm12144737
Vancouver
Yamamoto Y, Otsuka Y, Tokumasu K, Sunada N, Nakano Y, Honda H, et al. Utility of Serum Ferritin for Predicting Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Patients with Long COVID. Journal of Clinical Medicine. 2023;12(14):4737. doi:10.3390/jcm12144737
BibTeX
@article{Yamamoto2023,
author = {Yamamoto, Yukichika and Otsuka, Yuki and Tokumasu, Kazuki and Sunada, Naruhiko and Nakano, Yasuhiro and Honda, Hiroyuki and Sakurada, Yasue and Hasegawa, Toru and Hagiya, Hideharu and Otsuka, Fumio},
title = {Utility of Serum Ferritin for Predicting Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Patients with Long COVID},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {14},
pages = {4737},
doi = {10.3390/jcm12144737}
}
EUVIMED